Cerebrolysin

ApprovedSmall molecule

EEver Neuro Pharma GmbH

Cerebrolysin is one of 294 small molecule programs targeting Cerebral Palsy. It is currently in Approved.

Indications

Total Trials

Active Trials

293

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral PalsyActive, not recruiting

AnosmiaActive, not recruiting

StrokeActive, not recruiting

Down SyndromeActive, not recruiting

Brain InjuryActive, not recruiting

DeliriumActive, not recruiting

EncephalopathyActive, not recruiting

Vascular DementiaActive, not recruiting

DementiaActive, not recruiting

Subarachnoid HemorrhageActive, not recruiting

Cerebral PalsyPhase 2

Active, not recruiting

AnosmiaApproved

Active, not recruiting

StrokePhase 3

Active, not recruiting

Down SyndromePhase 2

Active, not recruiting

Brain InjuryPreclinical

Active, not recruiting

DeliriumPreclinical

Active, not recruiting

EncephalopathyPhase 2

Active, not recruiting

Vascular DementiaApproved

Active, not recruiting

DementiaApproved

Active, not recruiting

Subarachnoid HemorrhagePhase 2/Phase 3

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Cerebrolysin

EEver Neuro Pharma GmbH

Approved

9 2

Activase

Roche

Preclinical

19 3

Zometa

Pfizer

Preclinical

1 4

Proamatine

Pradaxa

3 6

Botox

RRevance Therapeutics, Inc.

Preclinical

2 7

Zantac 150

CChattem

Preclinical

1 8

Haldol

DDePuy Orthopaedics

Preclinical

1 9

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Botulinum Toxin a

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

CADASIL

NCT05755997

Q3 2027

Phase 1Not yet recruiting

Stroke

NCT06339411

Clinical

Trials by Indication[1]

Stroke9 trials

Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized Controlled Study

Unknown status·YYonsei University·Phase 4·NCT04913831·30 enrolled

IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE

Terminated·EEver Neuro Pharma GmbH·Phase 2·NCT04124367·4 enrolled

Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT

Unknown status·PPomeranian Medical University Szczecin·Phase 2/3·NCT05124353·100 enrolled

Show 6 more trials

Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke

Completed·EEver Neuro Pharma GmbH·Phase 3·NCT00840671·119 enrolled

Cerebrolysin REGistry Study in Stroke

Terminated·EEver Neuro Pharma GmbH··NCT02541227·1,823 enrolled

Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness

Completed·EEver Neuro Pharma GmbH··NCT03480698·1,851 enrolled

A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergoing EndoVascular Treatment (EVT)

Unknown status·SShaare Zedek Medical Center·N/A·NCT06070753·30 enrolled

Exploring Cerebrolysin in Late Thrombectomy for Stroke: Blood-brain Barrier Biomarkers and Imaging Insights

Not yet recruiting·—·Phase 1·NCT06339411·100 enrolled

Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke

Completed·SSamsung Medical Center·Phase 4·NCT02768571·80 enrolled

Ischemic stroke6 trials

Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.

Completed·—·Phase 3·NCT01388738·30 enrolled

The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke

Completed·EEver Neuro Pharma GmbH·Phase 4·NCT00868283·1,071 enrolled

Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke

Completed·SShanghai 6th People's Hospital·Phase 1/2·NCT02149875·84 enrolled

Show 3 more trials

Efficacy of Cerebrolysin Treatment as an add-on Therapy to Mechanical Thrombectomy in Acute Ischemic Stroke.

Unknown status·MMilitary Institute od Medicine National Research Institute·Phase 3·NCT04904341·50 enrolled

Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm

Unknown status·—·Phase 4·NCT02581371·30 enrolled

Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke

Unknown status·HHospital Universitario Dr. Jose E. Gonzalez·Phase 4·NCT06273020·60 enrolled

Brain Injury3 trials

Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU

Completed·—·Phase 3·NCT06052787·150 enrolled

Evaluation of the Effect of Neuroprotective Drug on Treatment Result in Patients After Traumatic Brain Injury

Completed·PPomeranian Medical University Szczecin··NCT05807503·56 enrolled

The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery

Terminated·EEver Neuro Pharma GmbH·Phase 4·NCT01606111·46 enrolled

Delirium2 trials

Cerebrolysin in Critically Ill Patients With Delirium

Enrolling by invitation·MMedical University of Lublin·N/A·NCT06677502·500 enrolled

Cerebrolysin in Prevention of Postoperative Delirium in Cardiac Surgery

Unknown status·MMedical University of Lublin·N/A·NCT05864677·100 enrolled

Anosmia2 trials

Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants

Completed·SSherifa Ahmed Hamed·Phase 4·NCT06208540·160 enrolled

Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia

Completed·—·Phase 3·NCT04830943·250 enrolled

12 more indications

Prolonged Disorders of Consciousness1 trial

Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness

Unknown status·KKonkuk University Medical Center·Phase 4·NCT04427241·12 enrolled

Vascular Dementia1 trial

A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia

Completed·EEver Neuro Pharma GmbH·Phase 4·NCT00947531·242 enrolled

Encephalopathy1 trial

Study of Cerebrolysin for Treatment of Infants With History of Neonatal Hypoxic Ischemic Encephalopathy

Completed·SSahar M.A. Hassanein, MD·Phase 2·NCT01059461·40 enrolled

Prednisolone1 trial

Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy

Recruiting·OOctober 6 University·Phase 1/2·NCT05821075·90 enrolled

Basilar Artery Occlusion1 trial

Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion

Not yet recruiting·UUniversity Hospital Sestre Milosrdnice·Phase 1·NCT06489925·20 enrolled

Cerebral Palsy1 trial

Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral Palsy

Unknown status·—·Phase 2·NCT02116348·100 enrolled

Subarachnoid Hemorrhage1 trial

Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage

Completed·KKwong Wah Hospital·Phase 2/3·NCT01787123·50 enrolled

Down syndrome1 trial

the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome

Completed·MMansoura University Children Hospital·Phase 2·NCT04751136·64 enrolled

CADASIL1 trial

CERebrolysin In CADASIL

Active, not recruiting·EEver Neuro Pharma GmbH·Phase 2·NCT05755997·30 enrolled

Neurodevelopment1 trial

Cerebrolysin and Neurodevelopment in Preterm Infants

Completed·MMansoura University Children Hospital·Phase 1·NCT03506841·60 enrolled

Dementia1 trial

Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)

Withdrawn·EEver Neuro Pharma GmbH·Phase 4·NCT01822951

Unspecified1 trial

Hair Repigmentation During Cerebrolysin Therapy

Completed·UUniversidad Autonoma de Nuevo Leon·N/A·NCT05288465·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for Cerebrolysin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cerebrolysin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cerebrolysin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ever Neuro Pharma GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: EEver Neuro Pharma GmbH

Cerebrolysin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Trials by Indication[1]

Stroke9 trials

Ischemic stroke6 trials

Brain Injury3 trials

Delirium2 trials

Anosmia2 trials

Prolonged Disorders of Consciousness1 trial

Vascular Dementia1 trial

Encephalopathy1 trial

Prednisolone1 trial

Basilar Artery Occlusion1 trial

Cerebral Palsy1 trial

Subarachnoid Hemorrhage1 trial

Down syndrome1 trial

CADASIL1 trial

Neurodevelopment1 trial

Dementia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News